...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS care. >Adherence to combined Lamivudine+Zidovudine versus individual components: A community-based retrospective medicaid claims analysis.
【24h】

Adherence to combined Lamivudine+Zidovudine versus individual components: A community-based retrospective medicaid claims analysis.

机译：坚持拉米夫定+齐多夫定联合治疗与个体治疗的依从性：基于社区的回顾性药物声明分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adherence to a fixed dose combination of dual nucleoside antiretroviral therapy was compared between human immunodeficiency virus (HIV)-infected patients newly started on a fixed dosed combination of lamivudine (3TC) 150 mg/zidovudine (ZDV) 300 mg versus its components taken as separate pills. Medicaid pharmacy claims data were used for analyses. To examine the association between treatment group and medication adherence, three types of multivariate regressions were employed. In addition, all regressions were conducted for the whole population using data from 1995 to 2001 as well as a subpopulation, which excluded data prior to September 1997. Model covariates included patient characteristics, healthcare utilization, and non-study antiretroviral therapy use. The likelihood of >/=95% adherence among patients on combination therapy was three times greater than patients taking 3TC and ZDV in separate pills. Also, combination therapy patients had on average 1.4 fewer adherence failures per year of follow-up and nearly double the time to adherence failure compared to the separate pills group. Consistency among study results suggests that fixed dose combination therapies such as lamivudine (3TC) 150 mg/ zidovudine (ZDV) 300 mg should be considered when prescribing HIV treatment that includes an appropriate dual nucleoside.
机译：在新开始使用固定剂量拉米夫定（3TC）150 mg /齐多夫定（ZDV）300 mg组合开始的人类免疫缺陷病毒（HIV）感染患者之间比较了双核苷酸抗逆转录病毒疗法对固定剂量组合的依从性药。医疗补助药房索赔数据用于分析。为了检查治疗组和药物依从性之间的关联，采用了三种类型的多元回归。此外，所有回归均使用1995年至2001年的数据以及亚人群进行，所有人群均排除了1997年9月之前的数据。模型协变量包括患者特征，医疗保健利用率和非研究性抗逆转录病毒疗法的使用。接受联合治疗的患者中> / = 95％依从性的可能性是单独服用3TC和ZDV的患者的三倍。而且，与单独的药丸组相比，联合治疗患者每年随访的依从性失败平均少1.4倍，而依从性失败的时间几乎增加一倍。研究结果之间的一致性表明，在开处方包括适当双核苷的HIV治疗时，应考虑使用固定剂量的联合疗法，例如拉米夫定（3TC）150毫克/齐多夫定（ZDV）300毫克。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号